Rob Cerwinski, managing partner, is a seasoned patent litigator and IP strategist with 20+ years of experience at premier U.S. law firms helping international clients launch biopharma products into the highly-competitive U.S. market. Mr. Cerwinski specializes in helping companies devise cost-effective strategies to navigate the complex and intertwined legal, regulatory and financial hurdles that can delay or prevent product launch. His successes in pre-litigation strategy and in the courtroom have driven the launch of 20+ biopharma products in the U.S. and Europe. Mr. Cerwinski holds a Master of Science Degree in molecular biology and has a deep understanding of the science, business and regulation of biopharma product development, manufacture and marketing. Mr. Cerwinski co-founded the industry-leading biosimilars practice at Goodwin Procter LLP and is a recognized global authority on biosimilars. He is Senior Editor of the leading legal treatise in the field, Guide to Biosimilars Litigation and Regulation in the U.S. (published by Thomson-Reuters) and founded Goodwin’s award-winning biosimilars blog, Big Molecule Watch and its companion blog, Big Molecule Watch China. Mr. Cerwinski was named an IAM Global Leader in Intellectual Property Law in 2021, 2022 and 2023 and is ranked in the Gold Tier of the IAM Patent 1000.
Mr. Cerwinski has been interviewed extensively by Dow Jones, Forbes, the Center for Biosimilars, Bloomberg, SCRIPS, The Pink Sheet, and other publications. Thought leadership highlights include:
Mr. Cerwinski is a member of the New York City Bar Association, the New York State Bar Association, the New York Intellectual Property Law Association, the American Intellectual Property Law Association and the American Bar Association.
Prior to forming Gemini, Mr. Cerwinski was a partner at Goodwin Procter LLP in New York City. Before joining Goodwin in 2014, Mr. Cerwinski was a partner at Kenyon & Kenyon LLP. Before pursuing a career in law, he worked for a major Japanese pharmaceutical company in Tokyo assisting with intellectual property matters concerning biotechnology products.
Mr. Cerwinski is ranked in the Gold Tier of the IAM Patent 1000 – The World’s Leading Patent Professionals as one of the world’s leading patent litigators (2017, 2019-2022) and as an IAM Global Leader in 2021, 2022 and 2023.
Legal 500 USA – IP Litigation (2018)
Mr. Cerwinski is admitted to practice in New York, as well as before the U.S. District Court for the Southern District of New York and the U.S. Court of Appeals for the Federal Circuit.